CSF1R and pulmonary fibrosis: The aforementioned results suggested that the SHP-1 agonist SC-43 may exert its anti-pulmonary fibrosis activities, at least partially, by transcriptionally reducing the expression of CSF1R in macrophages, which leads to the apoptosis of macrophages and reshaping of the immunofibrotic niche.